



an Open Access Journal by MDPI

Neutrophilic Inflammation: Molecular Mechanisms and Drug Discovery

Guest Editors:

Dr. Po-Jen Chen

Department of Medical Research,
E-Da Hospital, Kaohsiung 824410,
Taiwan

Dr. Kuei-Hung Lai

Program in the Clinical Drug
Development of Herbal Medicine,
Taipei Medical University, Taipei
11031, Taiwan

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editors

Dear Colleagues,

The Special Issue "Neutrophilic Inflammation: Molecular Mechanisms and Drug Discovery" aims to provide a comprehensive overview of the molecular mechanisms underlying neutrophilic inflammation, as well as the current state of drug discovery efforts targeting this process. Neutrophilic inflammation plays a critical role in the pathogenesis of various diseases, including acute respiratory distress syndrome, chronic obstructive pulmonary disease sepsis, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, and cancer. The Special Issue will cover a broad range of topics, including neutrophil recruitment and activation, signaling pathways, the role of neutrophils in tissue damage and repair, and the development of novel therapeutic strategies. The ultimate goal is to promote a better understanding of the complex biology of neutrophilic inflammation and to facilitate the identification of new drug targets for treating inflammatory diseases. The Issue welcomes original research articles, reviews, and perspectives that cover any aspect of neutrophilic inflammation and drug discovery.

Dr. Po-Jen Chen

Dr. Kuei-Hung Lai

Guest Editors



mdpi.com/si/167550

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)